Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

Pfizer

Status: Completed

Conditions: Chronic Myeloid Leukaemia

Treatments: Drug: Imatinib; Drug: Ponatinib; Drug: Dasatinib; Drug: Bosutinib; Drug: Nilotinib

Study type: Observational

Funder types: Industry

Identifiers

NCT05286528

B1871064

Details and patient eligibility

About

The objectives of this study are to describe patient demographics, clinical and disease characteristics and treatment patterns of Chronic Lymphoid Leukaemia (CML) in Hungary.

The primary endpoint of this study is the overall survival of CML patients treated with tyrosine kinase inhibitors in Hungary. The Overall Survival (OS) of all enrolled patients, OS by sequence pattern and by the number of treatment lines will be analyzed.

Secondary objectives are description of the treatment length in 1st and later lines, incidence and prevalence of CML, the patient demographics (as age, gender, comorbidities), average number of patients' comorbidities, most frequent comorbidities and patient number with comorbidities at baseline and at different treatment lines by investigated Thyrosine Kinase Inhibitor (TKI), distribution of the investigated TKI therapies by treatment lines

Enrollment: 1,484 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Female and male patients diagnosed with chronic myeloid leukemia
• Patients receiving tyrosine kinase inhibitor therapy under the terms of the current marketing authorization

Exclusion criteria

• Patients receiving TKI for non-CML diagnoses

Trial design